Hyperglycemia is common among patients with acute myocardial infarction (AMI) and is associated with high risk of mortality and morbidity. However, the relationship between admission plasma glucose (APG) levels and mortality in diabetic and nondiabetic patients with AMI needs further investigation. The aim of this study was to investigate the relationship between APG level and short-term mortality and morbidity after AMI.
This is a prospective study of 79 consecutive patients with AMI followed up for 90 days. Medical history, as well as demographic and clinical baseline characteristics, of the patients was obtained from Al-Watni Governmental Hospital medical records. The patients were divided into four groups based on APG levels. Patients' health status was followed up by phone call interviews with the patients and their families. Follow-up data were further confirmed using patients' medical records at the hospital. The phone interviews investigated all causes of death or congestive heart failure (CHF) or re-infarction.
The mean age of patients was 61.9 ± 12.3 years. At the time of hospital admission, the median PG level was 162 mg/dl. During the 3-month follow-up, overall mortality was 20.3% and was increased to 56.3% in patients with glucose levels >200 mg/dl. Mortality was comparable (21.9% vs. 19.1%; P > 0.05) between diabetic and nondiabetic patients. Nonfatal adverse outcomes in the form of combined CHF and re-infarction were highest in group IV and lowest in group I.
Our study demonstrates that high APG level is common in patients with AMI and is associated with high risk of mortality and morbidity among patients with or without diabetes mellitus. In fact, our study showed that nondiabetic patients with high APG have higher risk of mortality than patients with a known history of diabetes mellitus.
Objectives To measure the frequency of
herbal medicine use among patients with diabetes mellitus in Palestine; to
determine demographic characteristics that may increase the likelihood of
Complementary and Alternative Medicine (CAM) use and to find out how benefits,
if any, were perceived by patients.
Method Cross-sectional survey of
patients attending the outpatient diabetes departments at 7 Governmental
Hospitals. The method was based on semi-structured questionnaires.
Results A
total of 1883 patients with diabetes were interviewed. Of the participants,
51.9% (n = 977) reported taking herbs primarily bought from
Palestine (98%) and used in crude form mainly as decoctions (44.1%). The five
most common herbal products used were: Trigonella berythea (Fabaceae) (n = 191,
19.6%), Rosmarinus officinalis (Lamiaceae) (n = 132,
13.5%), Olea europaea (Oleaceae) (n = 131, 13.4%), Teucrium
capitatum (Lamiaceae) (n = 111, 11.4%), and Cinnamomum
zeylanicum (Lauraceae) (n = 105, 10.8%). Most CAM users
were above 40 years old 79.6% (n = 778), predominantly female
(53.2%) and residents of refugee camps and rural areas (59.3, and 53.5,
respectively). The recommendations of a family member or friend was the main
factor prompting the use of CAM (40.2 and 37.1%). Most CAM users (71.7%) were
satisfied with the perceived effects. Interestingly, 68% of patients recruited
in the study did not disclose CAM use to their physicians or pharmacists.
Conclusion
Use of herbal therapies in diabetes is highly prevalent in Palestine. More
than 70% of those using CAM (977, 51.9%) reported positive benefits including a
feeling of slowing down disease progression, symptom relief, disease resolution
or a reduction in the side effects of allopathic medication. Use of CAM should
be explored with patients before clinical decisions are made. There is a need
for health education relating to herbal use in conjunction with conventional
medicines in diabetes.
Aims : Hyperglycemia is common among patients with acute myocardial infarction (AMI) and is associated with high risk of mortality and morbidity. However, the relationship between admission plasma glucose (APG) levels and mortality in diabetic and nondiabetic patients with AMI needs further investigation. The aim of this study was to investigate the relationship between APG level and short-term mortality and morbidity after AMI.
Materials And Methods : This is a prospective study of 79 consecutive patients with AMI followed up for 90 days. Medical history, as well as demographic and clinical baseline characteristics, of the patients was obtained from Al-Watni Governmental Hospital medical records. The patients were divided into four groups based on APG levels. Patients' health status was followed up by phone call interviews with the patients and their families. Follow-up data were further confirmed using patients' medical records at the hospital. The phone interviews investigated all causes of death or congestive heart failure (CHF) or re-infarction.
Results : The mean age of patients was 61.9 ± 12.3 years. At the time of hospital admission, the median PG level was 162 mg/dl. During the 3-month follow-up, overall mortality was 20.3% and was increased to 56.3% in patients with glucose levels >200 mg/dl. Mortality was comparable (21.9% vs. 19.1%; P > 0.05) between diabetic and nondiabetic patients. Nonfatal adverse outcomes in the form of combined CHF and re-infarction were highest in group IV and lowest in group I.
Conclusion :Our study demonstrates that high APG level is common in patients with AMI and is associated with high risk of mortality and morbidity among patients with or without diabetes mellitus. In fact, our study showed that nondiabetic patients with high APG have higher risk of mortality than patients with a known history of diabetes mellitus
Aims :Hyperglycemia is common among patients with acute myocardial infarction (AMI) and is associated with high risk of mortality and morbidity. However, the relationship between admission plasma glucose (APG) levels and mortality in diabetic and nondiabetic patients with AMI needs further investigation. The aim of this study was to investigate the relationship between APG level and short-term mortality and morbidity after AMI.
Materials And Methods : This is a prospective study of 79 consecutive patients with AMI followed up for 90 days. Medical history, as well as demographic and clinical baseline characteristics, of the patients was obtained from Al-Watni Governmental Hospital medical records. The patients were divided into four groups based on APG levels. Patients' health status was followed up by phone call interviews with the patients and their families. Follow-up data were further confirmed using patients' medical records at the hospital. The phone interviews investigated all causes of death or congestive heart failure (CHF) or re-infarction.
Results :The mean age of patients was 61.9 ± 12.3 years. At the time of hospital admission, the median PG level was 162 mg/dl. During the 3-month follow-up, overall mortality was 20.3% and was increased to 56.3% in patients with glucose levels >200 mg/dl. Mortality was comparable (21.9% vs. 19.1%; P > 0.05) between diabetic and nondiabetic patients. Nonfatal adverse outcomes in the form of combined CHF and re-infarction were highest in group IV and lowest in group I.
Conclusion: Our study demonstrates that high APG level is common in patients with AMI and is associated with high risk of mortality and morbidity among patients with or without diabetes mellitus. In fact, our study showed that nondiabetic patients with high APG have higher risk of mortality than patients with a known history of diabetes mellitus
Aims : Hyperglycemia is common among patients with acute myocardial infarction (AMI) and is associated with high risk of mortality and morbidity. However, the relationship between admission plasma glucose (APG) levels and mortality in diabetic and nondiabetic patients with AMI needs further investigation. The aim of this study was to investigate the relationship between APG level and short-term mortality and morbidity after AMI.
Materials And Methods :This is a prospective study of 79 consecutive patients with AMI followed up for 90 days. Medical history, as well as demographic and clinical baseline characteristics, of the patients was obtained from Al-Watni Governmental Hospital medical records. The patients were divided into four groups based on APG levels. Patients\' health status was followed up by phone call interviews with the patients and their families. Follow-up data were further confirmed using patients\' medical records at the hospital. The phone interviews investigated all causes of death or congestive heart failure (CHF) or re-infarction.
Results: The mean age of patients was 61.9 ± 12.3 years. At the time of hospital admission, the median PG level was 162 mg/dl. During the 3-month follow-up, overall mortality was 20.3% and was increased to 56.3% in patients with glucose levels >200 mg/dl. Mortality was comparable (21.9% vs. 19.1%; P > 0.05) between diabetic and nondiabetic patients. Nonfatal adverse outcomes in the form of combined CHF and re-infarction were highest in group IV and lowest in group I.
Conclusion : Our study demonstrates that high APG level is common in patients with AMI and is associated with high risk of mortality and morbidity among patients with or without diabetes mellitus. In fact, our study showed that nondiabetic patients with high APG have higher risk of mortality than patients with a known history of diabetes mellitus.